NFKB1 and diabetes mellitus: Studies had shown that Isorhamnetin could hinder IKK/IKB/NF‐KB/iNOS signaling pathway and reduce interleukin‐1β(IL‐1β), interleukin‐6(IL‐6), and other inflammatory factors to achieve the effect of anti‐DM [47].